Nanost lands $25K TEDCO grant for portable blood testing

What's the deal? TEDCODealroom has a profile for this one. Try Dealroom →, the Maryland Technology Development Corporation, has awarded a $25,000 grant to Nanost through its Concept Capital programme. The Gaithersburg-based startup is building a portable blood testing platform that brings rapid biomarker measurements closer to the point of care.

Nanost is initially targeting pharmaceutical clinical research but sees broader applications in emergency medicine, neurodegenerative disease, military medicine, rural healthcare, and decentralised healthcare settings.

"Nanost is committed to turning an innovative idea into an actionable solution for both patients and providers," said Justin Ferguson, innovation manager at TEDCO's Venture Development unit.

Why now? Nanost has been deepening its relationship with TEDCO since 2024, when it first received a Network Advisor. The company later tapped several TEDCO programmes, including the SBIR/STTR Proposal Lab and the Federal Labs Leveraging Innovation to Products (FLLIP) Pilot Program. The Concept Capital grant marks the next step in that progression.

Maryland's life sciences ecosystem — anchored by the National Institutes of Health and the US Food and Drug Administration — gives diagnostics startups like Nanost proximity to federal partners and a deep talent pool.

What could go wrong? A $25,000 grant is seed-stage funding in the truest sense. Portable diagnostics is a capital-intensive field with steep regulatory hurdles, and Nanost will need substantially more investment to move from concept to commercialisation.

The company also faces competition from established point-of-care testing players. Proving clinical accuracy and reliability outside a traditional lab setting remains a persistent challenge for portable platforms.

The signal: Decentralised diagnostics is a growing theme in healthcare, accelerated by the pandemic-era push for testing outside hospital walls. Public funding bodies like TEDCO are placing small, early bets on startups that could reshape how and where blood tests happen — from clinical trials to battlefield medicine to rural clinics.

For Maryland, the grant reflects a broader strategy to convert the state's federal research assets into commercial startups, keeping innovation local.

Read more: citybiz.co